Analyst consensus rating
Attovia Therapeutics Analyst Rating: Strong Buy
Direct answer
Attovia Therapeutics's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $42.20.
Forecast evidence checked September 12, 2026.
Get free Attovia Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $22.79
- Average price target
- $42.20
- High price target
- $52.00
- Low price target
- $30.00
- Low target gap
- +31.6%
- Target upside
- +85.2%
- High target gap
- +128.2%
- Target range width
- 96.5%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- September 12, 2026
- Valid through
- September 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Attovia Therapeutics?
Attovia Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $42.20.
How far are Attovia Therapeutics's low and high targets from the recorded price?
The low target implies +31.6%, while the high target implies +128.2%.
How many analysts are included in Attovia Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Attovia Therapeutics's target upside or downside calculated?
The average target of $42.20 is divided by the recorded price of $22.79, then one is subtracted to produce +85.2%. This does not guarantee a future return.
When was Attovia Therapeutics's analyst forecast verified?
The data was verified on 2026-09-12. The dataset is valid through 2026-09-19.